HUM Quote, Financials, Valuation and Earnings

Centene Corp. has a net margin of -2.39% compared to Humana, Inc.'s net margin of -2.21%. Humana, Inc.'s return on equity of 6.77% beat Centene Corp.'s return on equity of -27.11%.

Humana, Inc. has a consensus price target of $231.57, signalling upside risk potential of 25.78%. On the other hand Centene Corp. has an analysts' consensus of $44.18 which suggests that it could grow by 8.86%. Given that Humana, Inc. has higher upside potential than Centene Corp., analysts believe Humana, Inc. is more attractive than Centene Corp..

Humana, Inc. has a beta of 0.437, which suggesting that the stock is 56.287% less volatile than S&P 500. In comparison Centene Corp. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.703%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.92%. Centene Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana, Inc. pays 35.98% of its earnings as a dividend. Centene Corp. pays out -- of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.5B, which are smaller than Centene Corp. quarterly revenues of $49.7B. Humana, Inc.'s net income of -$776M is higher than Centene Corp.'s net income of -$1.1B. Notably, Humana, Inc.'s price-to-earnings ratio is 18.77x while Centene Corp.'s PE ratio is 8.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.17x versus 0.10x for Centene Corp.. Usually stocks with elevated PS ratios are considered overvalued.

CVS Health Corp. has a net margin of -2.39% compared to Humana, Inc.'s net margin of 2.77%. Humana, Inc.'s return on equity of 6.77% beat CVS Health Corp.'s return on equity of 2.28%.

Humana, Inc. has a consensus price target of $231.57, signalling upside risk potential of 25.78%. On the other hand CVS Health Corp. has an analysts' consensus of $94.84 which suggests that it could grow by 20.85%. Given that Humana, Inc. has higher upside potential than CVS Health Corp., analysts believe Humana, Inc. is more attractive than CVS Health Corp..

Humana, Inc. has a beta of 0.437, which suggesting that the stock is 56.287% less volatile than S&P 500. In comparison CVS Health Corp. has a beta of 0.496, suggesting its less volatile than the S&P 500 by 50.368%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.92%. CVS Health Corp. offers a yield of 3.39% to investors and pays a quarterly dividend of $0.67 per share. Humana, Inc. pays 35.98% of its earnings as a dividend. CVS Health Corp. pays out 191.23% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but CVS Health Corp.'s is not.

Humana, Inc. quarterly revenues are $32.5B, which are smaller than CVS Health Corp. quarterly revenues of $105.7B. Humana, Inc.'s net income of -$776M is lower than CVS Health Corp.'s net income of $2.9B. Notably, Humana, Inc.'s price-to-earnings ratio is 18.77x while CVS Health Corp.'s PE ratio is 56.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.17x versus 0.25x for CVS Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -2.39% compared to Humana, Inc.'s net margin of -1.41%. Humana, Inc.'s return on equity of 6.77% beat Molina Healthcare, Inc.'s return on equity of 10.89%.

Humana, Inc. has a consensus price target of $231.57, signalling upside risk potential of 25.78%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $167.81 which suggests that it could grow by 23.98%. Given that Humana, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Humana, Inc. is more attractive than Molina Healthcare, Inc..

Humana, Inc. has a beta of 0.437, which suggesting that the stock is 56.287% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.546%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.92%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana, Inc. pays 35.98% of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.5B, which are larger than Molina Healthcare, Inc. quarterly revenues of $11.4B. Humana, Inc.'s net income of -$776M is lower than Molina Healthcare, Inc.'s net income of -$160M. Notably, Humana, Inc.'s price-to-earnings ratio is 18.77x while Molina Healthcare, Inc.'s PE ratio is 15.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.17x versus 0.16x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group, Inc. has a net margin of -2.39% compared to Humana, Inc.'s net margin of 0.19%. Humana, Inc.'s return on equity of 6.77% beat UnitedHealth Group, Inc.'s return on equity of 17.57%.

Humana, Inc. has a consensus price target of $231.57, signalling upside risk potential of 25.78%. On the other hand UnitedHealth Group, Inc. has an analysts' consensus of $364.63 which suggests that it could grow by 24.37%. Given that Humana, Inc. has higher upside potential than UnitedHealth Group, Inc., analysts believe Humana, Inc. is more attractive than UnitedHealth Group, Inc..

Humana, Inc. has a beta of 0.437, which suggesting that the stock is 56.287% less volatile than S&P 500. In comparison UnitedHealth Group, Inc. has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.094%.

Humana, Inc. has a quarterly dividend of $0.89 per share corresponding to a yield of 1.92%. UnitedHealth Group, Inc. offers a yield of 2.98% to investors and pays a quarterly dividend of $2.21 per share. Humana, Inc. pays 35.98% of its earnings as a dividend. UnitedHealth Group, Inc. pays out 65.97% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana, Inc. quarterly revenues are $32.5B, which are smaller than UnitedHealth Group, Inc. quarterly revenues of $113.2B. Humana, Inc.'s net income of -$776M is lower than UnitedHealth Group, Inc.'s net income of $218M. Notably, Humana, Inc.'s price-to-earnings ratio is 18.77x while UnitedHealth Group, Inc.'s PE ratio is 22.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana, Inc. is 0.17x versus 0.60x for UnitedHealth Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.